DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20214713
Published: 2021-11-26

Utility of bile esculin azide agar for screening of stool samples for vancomycin resistant enterococci from patients with gut colonization

Deepa Pramod Devhare, Sae Satish Pol, Varsha Pendse

Abstract


Background: Due to increased prevalence of vancomycin resistant enterococci (VRE) in hospital settings as an important nosocomial pathogen, microbiology laboratories should be prepared with test protocol for prompt detection and reporting of these resistant organisms. This helps in appropriate treatment of patients without delay and implementation of infection control measures in order to prevent spread of such infections. With this background present study was conducted to demonstrate utility of bile esculin azide agar with vancomycin (BEAV) for screening of enterococci for vancomycin drug resistance.

Methods: Over a period of one year 200 stool samples were collected from hospitalized patients in a tertiary care hospital. Samples were inoculated on bile esculin azide agar with vancomycin (6ug/ml) to screen for vancomycin drug resistance in enterococci isolated from stool samples. Vancomycin drug resistance was confirmed by agar dilution method.

Results: Out of 200 stool samples collected from hospitalized patients, 13 (6.5%) samples showed growth on bile esculin azide agar with vancomycin (6 µg/ml). Of these 13 isolates, 12 (92.3%) isolates were confirmed as VRE by agar dilution method and demonstrated minimum inhibitory concentration (MIC) of ≥32 µg/ml and all 12 isolates were identified as E. faecium. One (7.7%) isolate grown on BEAV was identified as E. gallinarum and showed MIC value of 8 µg/ml.

Conclusions: Present study recommends use of bile esculin azide agar with vancomycin (6 µg/ml) as a screening medium for isolation of VRE from stool samples which usually carries mixed commensal flora of gastrointestinal tract.


Keywords


Agar dilution method, Bile esculin azide agar with vancomycin, VRE

Full Text:

PDF

References


Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol. 1995;33:24-7.

Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol. 1995;16:105-13.

Pack insert- Bile esculin azide agar. M493I. Himedia private limited, Mumbai, Maharastra. Available from: https://himedialabs.com/TD/M493I.pdf. Accessed on 12 January 2014.

Jensen BJ. Screening specimens for vancomycin-resistant enterococcus. Lab Med. 1996;27(1):53-5.

Collee JG, Fraser AG, Marmion, Simmons BP. A Mackie and McCartney Practical Medical Microbiology. 14th edn. New York: Churchill Livingstone; 2006.

Wayne P. Clinical and Laboratory Standards Institute (CLSI) performance standards for antimicrobial disk diffusion susceptibility tests 19th ed. approved standard. CLSI document M100-S19. 2009;29(2011):M100-S21.

Jorgensen J, Ferraro M. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Med Microbiol CID. 2009;49:1749.

Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC Jr, Colour Atlas and Textbook of Diagnostic Microbiology, 4th Edn. J. B. Lippinccott Company; 1992.

Jenkins S, Raskoshina L, Schuetz A. Comparison of performance of the novel chromogenic spectra VRE agar to that of bile esculin azide and campylobacter agars for detection of vancomycin-resistant enterococci in fecal samples. J Clin Microbiol. 2011:3947-9.

Facklam RR, Sahm DF. Enterococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology; 1995:308-313.

Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993;37:1563-71.

Tlaskalová-Hogenová H, Stepánková R, Hudcovic T, Tucková L, Cukrowska B, Lodinová-Zádníková R, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett. 2004;93(2-3):97-108.